Alnylam Pharmaceuticals, Inc. (ALNY)

NASDAQ: ALNY · Real-Time Price · USD

369.96

-0.95 (-0.26%)

At close: Jan 13, 2026, 4:00 PM EST

370.00

+0.04 (0.01%)

After-hours: Jan 13, 2026, 6:59 PM EST

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
AMVUTTRA Revenue	1.77B	970.45M	Log In	Log In	Log In	Upgrade
ONPATTRO Revenue	197.21M	252.86M	Log In	Log In	Log In	Upgrade
GIVLAARI Revenue	286.34M	255.87M	Log In	Log In	Log In	Upgrade
OXLUMO Revenue	185.36M	167.05M	Log In	Log In	Log In	Upgrade
Total Product Revenue	2.44B	1.65B	Log In	Log In	Log In	Upgrade
Roche - Collaboration Revenue	373.94M	119.49M	Log In	Log In	Log In	Upgrade
Regeneron Pharmaceuticals - Collaboration Revenue	136.78M	302.80M	Log In	Log In	Log In	Upgrade
Novartis AG - Collaboration Revenue	-	79.76M	Log In	Log In	Log In	Upgrade
Vir Biotechnology - Collaboration Revenue	-	-	Log In	Log In	Log In	Upgrade
Other - Collaboration Revenue (Pre-FY2023)	-	-	Log In	Log In	Log In	Upgrade
Other - Collaboration Revenue (Post-FY2022)	48.65M	8.18M	Log In	Log In	Log In	Upgrade
Total Collaboration Revenue	619.37M	510.22M	Log In	Log In	Log In	Upgrade
Royalty Revenue	148.04M	91.79M	Log In	Log In	Log In	Upgrade
Revenue (Other)	-559.37M	-510.22M	Log In	Log In	Log In	Upgrade
Revenue (Total)	3.21B	2.25B	Log In	Log In	Log In	Upgrade

Updated Oct 30, 2025. Data Source: Fiscal.ai.